{"entity":{"id":"nct02872103","kind":"trial","name":"Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","aka":[],"tldr":"A phase 3 trial of Efbemalenograstim alfa in Breast cancer, run by EVIVE Biotechnology, completed.","summary":"Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy is a phase 3 interventional study registered as NCT02872103 by EVIVE Biotechnology, with 122 participants recorded, started 2016-08 and reaching its primary completion in 2017-12-20. Interventions recorded: F-627, Placebo. Conditions recorded: Breast Cancer, Neutropenia.\n\nLinked to the drug Efbemalenograstim alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02872103","url":"https://clinicaltrials.gov/study/NCT02872103"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer","male-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["efbemalenograstim-alfa"],"companies":["evive-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02872103","phase":"3","setting":"A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","sponsor":"EVIVE Biotechnology","started":"2016-08","yearReported":2019,"enrolled":122,"enrolledBasis":"registry","outcomes":[{"endpoint":"The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo","primary":true,"unit":"days","arms":[{"name":"F-627","n":83,"value":1.3,"note":"SD 1.17; Figures from the ClinicalTrials.gov results section (first posted 2019-03-26), not from a publication"},{"name":"Placebo","n":39,"value":3.9,"note":"SD 1.35"}],"source":"https://clinicaltrials.gov/study/NCT02872103?tab=results"}]},"route":"/trials/nct02872103/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/"}],"drug":[{"id":"efbemalenograstim-alfa","kind":"drug","name":"Efbemalenograstim alfa","route":"/drugs/efbemalenograstim-alfa/"}],"company":[{"id":"evive-biotech","kind":"company","name":"Evive Biotech","route":"/companies/evive-biotech/"}]}}